Novel Biomarker Discovery for Diagnostic and Therapeutic Strategies in Prostate Cancer
Annual rept. 1 Mar 2013-28 Feb 2014
MIAMI UNIV FL
Pagination or Media Count:
The purpose of this grant is to identify, isolate and characterize high affinity aptamers that distinguish between prostate cancers that are likely to remain organ-confined and those with potential to metastasize, The scope of this pilot is to generate DNA aptamers that selectively react with a prostate cancer cell line that remains confined to the prostate LNCaP vs. a subpopulation of this cell line that has acquired the ability to metastasize aggressively, employing Cell-Selex and Aptamer-Facilitated Biomarker Discovery AptaBiD technology. Major Findings and Progress 1 Non-metastatic LNCaP-Pro-5 cells and metastatic LNCaP-LN3 cells have been provided by Curtis Pettaway, M.D. Anderson Cancer Center, Houston, Texas. 2 Parental LNCaP cells have been obtained from American Type Culture Collection. 3 Phenotypic validation aggressive vs. indolent growth has been carried out on all cell lines using the Boyden Chamber assay. 4 DNA 40 bp aptamer libraries have been generated. 5 12 rounds of Cell-Selex have been initiated. 6 Plan for next-generation sequencing and bioinformatic analysis pathway has been established to yield desired phenotype-specific DNA aptamers. Next steps will include NexGen sequencing and testing of DNA aptamer families on human clinical prostate cancer specimens.
- Genetic Engineering and Molecular Biology
- Medicine and Medical Research